BIOMAT Database Logo BIOMAT Database Logo

In vivo antibacterial activity of FK037, a novel parenteral broad-spectrum cephalosporin. 1993

Y Mine, and Y Watanabe, and H Sakamoto, and K Hatano, and Y Wakai, and T Kamimura, and S Tawara, and S Matsumoto, and F Matsumoto, and S Kuwahara
Product Development Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan.

FK037 has potent therapeutic activity against lethal systemic infections and experimental local infections due to a wide variety of Gram-positive and Gram-negative bacteria such as staphylococci, Streptococcus pneumoniae, Enterobacteriaceae and Pseudomonas aeruginosa in mice. In murine systemic infections, FK037 was the most effective of the cephalosporins and imipenem tested against highly methicillin-resistant Staphylococcus aureus (H-MRSA). It was more effective than ceftazidime against selected strains of S. aureus and Enterobacteriaceae, except Serratia marcescens and P. aeruginosa against which FK037 was as effective as ceftazidime and was as effective as cefpirome against all organisms tested, except MRSA and P. aeruginosa against which FK037 was more effective than cefpirome. These results correlated well with its in vitro activity. In murine local infections, with few exceptions, FK037 was more effective than ceftazidime and cefpirome against Klebsiella pneumonia in ED50 values and against methicillin-sensitive S. aureus (MSSA) subcutaneous abscess, pyelonephritis with Staphylococcus epidermidis, E. coli and P. aeruginosa, intrauterine infections with S. aureus and E. coli in reducing the number of viable bacteria in the abscess, kidneys and uterus. It is noteworthy that the therapeutic effects of FK037 were more potent than had been anticipated from its in vitro activity against local infections with staphylococci and P. aeruginosa when compared with ceftazidime or cefpirome. In addition, the therapeutic effects of FK037 were equipotent or superior to those of cefpirome and ceftazidime against pneumonia due to MSSA, K. pneumoniae and P. aeruginosa in reducing the number of viable bacteria in the lungs in mice using an in vivo pharmacokinetic model simulating human plasma concentrations after drip infusion of usual clinical doses (0.25 to 1.0 g for MSSA, 0.063 to 0.125 g for K. pneumoniae and 1.0 to 2.0 g for P. aeruginosa). FK037 induced an in vivo post-antibiotic effect (PAE) of 3.4 hours against a thigh infection with MSSA in neutropenic mice. These results strongly suggest that it has potential for clinical use against various infections due to bacteria which include staphylococci and P. aeruginosa.

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D008297 Male Males
D008813 Mice, Inbred ICR An inbred strain of mouse that is used as a general purpose research strain, for therapeutic drug testing, and for the genetic analysis of CARCINOGEN-induced COLON CANCER. Mice, Inbred ICRC,Mice, ICR,Mouse, ICR,Mouse, Inbred ICR,Mouse, Inbred ICRC,ICR Mice,ICR Mice, Inbred,ICR Mouse,ICR Mouse, Inbred,ICRC Mice, Inbred,ICRC Mouse, Inbred,Inbred ICR Mice,Inbred ICR Mouse,Inbred ICRC Mice,Inbred ICRC Mouse
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D011014 Pneumonia Infection of the lung often accompanied by inflammation. Experimental Lung Inflammation,Lobar Pneumonia,Lung Inflammation,Pneumonia, Lobar,Pneumonitis,Pulmonary Inflammation,Experimental Lung Inflammations,Inflammation, Experimental Lung,Inflammation, Lung,Inflammation, Pulmonary,Inflammations, Lung,Inflammations, Pulmonary,Lobar Pneumonias,Lung Inflammation, Experimental,Lung Inflammations,Lung Inflammations, Experimental,Pneumonias,Pneumonias, Lobar,Pneumonitides,Pulmonary Inflammations
D011704 Pyelonephritis Inflammation of the KIDNEY involving the renal parenchyma (the NEPHRONS); KIDNEY PELVIS; and KIDNEY CALICES. It is characterized by ABDOMINAL PAIN; FEVER; NAUSEA; VOMITING; and occasionally DIARRHEA. Necrotizing Pyelonephritis,Pyelonephritis, Acute Necrotizing,Pyelonephritides
D002463 Cell Membrane Permeability A quality of cell membranes which permits the passage of solvents and solutes into and out of cells. Permeability, Cell Membrane
D005260 Female Females
D000038 Abscess Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection. Abscesses
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Y Mine, and Y Watanabe, and H Sakamoto, and K Hatano, and Y Wakai, and T Kamimura, and S Tawara, and S Matsumoto, and F Matsumoto, and S Kuwahara
In vitro and in vivo antibacterial activities of FK037, a novel parenteral broad-spectrum cephalosporin.
February 1993, Antimicrobial agents and chemotherapy,
Y Mine, and Y Watanabe, and H Sakamoto, and K Hatano, and Y Wakai, and T Kamimura, and S Tawara, and S Matsumoto, and F Matsumoto, and S Kuwahara
FK037, a new parenteral cephalosporin with a broad antibacterial spectrum: synthesis and antibacterial activity.
February 1993, The Journal of antibiotics,
Y Mine, and Y Watanabe, and H Sakamoto, and K Hatano, and Y Wakai, and T Kamimura, and S Tawara, and S Matsumoto, and F Matsumoto, and S Kuwahara
Animal pharmacokinetics of FK037, a novel parenteral broad-spectrum cephalosporin.
January 1993, The Journal of antibiotics,
Y Mine, and Y Watanabe, and H Sakamoto, and K Hatano, and Y Wakai, and T Kamimura, and S Tawara, and S Matsumoto, and F Matsumoto, and S Kuwahara
In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
January 1994, Chemotherapy,
Y Mine, and Y Watanabe, and H Sakamoto, and K Hatano, and Y Wakai, and T Kamimura, and S Tawara, and S Matsumoto, and F Matsumoto, and S Kuwahara
In vitro and in vivo antibacterial activities of E1077, a novel parenteral cephalosporin with a broad antibacterial spectrum.
September 1992, Antimicrobial agents and chemotherapy,
Y Mine, and Y Watanabe, and H Sakamoto, and K Hatano, and Y Wakai, and T Kamimura, and S Tawara, and S Matsumoto, and F Matsumoto, and S Kuwahara
In vitro antibacterial activities of FK037: a new parenteral cephalosporin.
January 1995, Chemotherapy,
Y Mine, and Y Watanabe, and H Sakamoto, and K Hatano, and Y Wakai, and T Kamimura, and S Tawara, and S Matsumoto, and F Matsumoto, and S Kuwahara
In vitro antibacterial activity of FK037, a new parenteral broad-spectrum cephalosporin, against recent clinical isolates in the fields of obstetrics and gynecology.
January 1994, Chemotherapy,
Y Mine, and Y Watanabe, and H Sakamoto, and K Hatano, and Y Wakai, and T Kamimura, and S Tawara, and S Matsumoto, and F Matsumoto, and S Kuwahara
Antibacterial activity of BMY-28142, a novel broad-spectrum cephalosporin.
November 1986, The Journal of antibiotics,
Y Mine, and Y Watanabe, and H Sakamoto, and K Hatano, and Y Wakai, and T Kamimura, and S Tawara, and S Matsumoto, and F Matsumoto, and S Kuwahara
In-vitro and in-vivo antibacterial activity of LB10517, a novel catechol-substituted cephalosporin with a broad antibacterial spectrum.
April 1996, The Journal of antimicrobial chemotherapy,
Y Mine, and Y Watanabe, and H Sakamoto, and K Hatano, and Y Wakai, and T Kamimura, and S Tawara, and S Matsumoto, and F Matsumoto, and S Kuwahara
HR 810, a new parenteral cephalosporin with a broad antibacterial spectrum.
January 1983, Arzneimittel-Forschung,
Copied contents to your clipboard!